홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ANTX
#3609
AN2 Therapeutics, Inc. Common Stock
1.1
0
+1.85%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+1.85%
월간 변동
-7.56%
6달 변화
-3.51%
년간 변동율
+0.92%
이전 종가
1.0
8
Open
1.1
0
Bid
Ask
Low
1.1
0
High
1.1
0
양
1
마켓
주식
헬스케어
ANTX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
29.88 M
30.1 M
30.18 M
27.33 M
27.4 M
—
Valuation ratios
Enterprise value
-1.53 M
20.14 M
21.04 M
10.77 M
16.8 M
68.74 M
Price to earnings ratio
-0.55
-0.8
-0.9
-0.85
-1.11
-3.67
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
0.49
0.84
0.96
0.9
1.28
3.97
Price to book ratio
0.07
0.5
0.12
0.1
0.13
0.86
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.13
-0.08
-0.13
0.09
0.14
0.01
Return on equity %
0.15
-0.09
-0.15
0.09
0.16
0.01
Return on invested capital %
—
-1 397.79
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.75
10.07
9.29
11.67
12.52
43.56
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.4
-0.18
-0.35
-0.25
-0.21
-0.99
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
3.13
2.8
2.23
2.08
2.05
9.17
Net current asset value per share
3.27
2.89
2.31
2.24
2.11
9.56
Tangible book value per share
2.94
2.74
2.44
2.28
1.99
9.46
Working capital per share
2.94
2.6
2.07
2.05
1.95
8.66
Book value per share
2.94
2.74
2.44
2.28
1.99
9.46
뉴스
AN2 테라퓨틱스, Sarah Williams 회계 책임자로 임명
AN2 Therapeutics appoints Sarah Williams as principal accounting officer
FDA clears IND for epetraborole trial in mycobacterium abscessus
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
AN2 테라퓨틱스(ANTX) CFO Day, 8,883달러 상당 주식 매도
An2 therapeutics (ANTX): cfo Day sells $8883 in shares
AN2 테라퓨틱스 CSO, 6507달러 상당 주식 매도
An2 therapeutics CSO prior sells $6507 in stock
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock
An2 therapeutics chief development officer sells $9k in stock
AN2 Therapeutics partners with GSK to develop TB treatments